Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination SyndromeFinns även info om detta till exempel på Yahoo: https://uk.finance.yahoo.com/news/scientist-dr-akiko-iwasaki-joins-110100729.html
WALTHAM, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced the addition of Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale School of Medicine, to the SPEAR (Spike Protein Elimination and Recovery) Study Group. The SPEAR Study Group was launched earlier this month to focus on the biology and clinical disease or injury associated with persistent presence of spike antigen from SARS-CoV-2 virus or COVID-19 vaccines. (...)
(...) She also leads several groundbreaking studies into the pathobiology of Long COVID including the Yale LISTEN study and the Mount Sinai-Yale Long COVID study. Her recent work has helped shape the scientific understanding of how persistent SARS-CoV-2 spike protein or viral reservoirs may contribute to the ongoing symptoms in both Long COVID and PVS. https://www.biospace.com/press-releases/scientist-dr-akiko-iwasaki-joins-spear-study-group-to-investigate-monoclonal-antibodies-for-long-cov id-and-covid-19-post-vaccination-syndrome
The SPEAR Study Group will structure and guide anticipated clinical trials evaluating the effects of broadly neutralizing anti-SARS-CoV-2 spike protein monoclonal antibody (mAb) therapy in people suffering from Long COVID or Post-Vaccination Syndrome (PVS), conditions believed to be mediated by persistent viral reservoirs or circulating spike protein. Persistent SARS-CoV-2 spike protein has been identified in both populations, and both populations have overlapping manifestations of apparent clinical disease. As many as 5% or more of Americans have reported recent Long COVID symptoms, an extraordinary medical burden that will continue to evolve as infections continue in the U.S.Och de som då ingick i den, som nu utökats med Iwasaki:
The SPEAR Study Group includes the following investigators and researchers who, along with Invivyd, will collaborate on the design and anticipated execution of relevant clinical trials:Viktigt nu att du och Babar eller vad han hette snabbt kastar er på telefonen och ringer nämnda forskare och förklarar hur det ligger till.
Michael Peluso, M.D., MHS, Assistant Professor of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco
Amy Proal, Ph.D., Co-Founder and CEO, Polybio Research Foundation and Scientific Director, Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases (“CoRE”)
David Putrino, Ph.D., Nash Family Director of the Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases (“CoRE”) and Professor, Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai. https://www.biospace.com/press-releases/scientist-dr-akiko-iwasaki-joins-spear-study-group-to-investigate-monoclonal-antibodies-for-long-cov id-and-covid-19-post-vaccination-syndrome

Du måste vara medlem för att kunna kommentera